Meta analysis of clinical randomized controlled trial of Chinese and Western medicine in the treatment of myasthenia gravis

Objective: Systematic evaluation of the clinical efficacy of Chinese and Western medicine combined with therapies for myasthenia gravis. Method: Comprehensive retrieval of Chinese Journal Full Text Database (CNKI), Chinese Biomedical Documentation Service System, Wanfang Pharmaceutical Journal Database, VIP Chinese Science and Technology Journal Full Text Database (VIP), Pubmed, Cochrane Library, etc. Retrieving Chinese and Western medicine combined therapy to treat myotropic gravis Powerless randomized controlled clinical trial literature, time interval set to January 1, 2000 - December 31, 2017. Quality evaluation of inclusion in literature based on Jadad scoring criteria. Data analysis using Review Manager 5.3 Results: 22 randomized controlled clinical trials were eventually included in 1972 study subjects. Dedicated , 18 have observed effective efficiency, 17 studies have extracted valid data, 95% CI is [1.07, 1.25], P<0.001, and 4 have observed recurrence rates. Of these, 3 have extracted valid data, RR values are 0.11, 95% CI are [0.05, 0.23], P<0.001, with statistical differences; there were 7 observations of antiacetylcholine antibodies (AchR-ab), the trial group compared with the control group, with an MD value of -0.29, 95% CI of [-0.42, -0.16], P<0.05, the difference was statistically significant; eight were clinically absolute score, MD was -0.0.0.0.0.0.0.0.0.0.0.0.0 58, 95% CI was [-1.98, 0.81], P=0.41>0.05, and the difference was not statistically significant; 5 clinical relative scores were performed, MD values were 0.28, 95% CI were [0.03, 0.53], P=0.03<0.05, the difference was statistically significant. Conclusion: Chinese medicine combined to treat myasthenia gravis single Pure Western Medicine Treatment , with clear advantages in improving efficiency, reducing relapse rates and improving conditions.